相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
John P. O'Donnell et al.
CLINICAL INFECTIOUS DISEASES (2023)
Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
Dimitra Petropoulou et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report
Dana J. Holger et al.
OPEN FORUM INFECTIOUS DISEASES (2022)
675. Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)
Drew Lewis et al.
Open Forum Infectious Diseases (2022)
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects
John O'Donnell et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review
M. Nguyen et al.
JOURNAL OF APPLIED MICROBIOLOGY (2021)
In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones
Carolina S. Nodari et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections
Jessica Howard-Anderson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
Adam B. Shapiro et al.
FRONTIERS IN MICROBIOLOGY (2021)
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
Giacomo Luci et al.
ANTIBIOTICS-BASEL (2021)
A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria
Anders N. Kristoffersson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Olexiy Sagan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
Jason D. Lickliter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
Qiwen Yang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
Harald Seifert et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
Rosalino Vazquez-Lopez et al.
ANTIBIOTICS-BASEL (2020)
Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen
Carole Ayoub Moubareck et al.
ANTIBIOTICS-BASEL (2020)
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
Melissa D. Barnes et al.
MBIO (2019)
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
John O'Donnell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam
Pratik Bhagunde et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
David C. Griffith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Matt Shirley
DRUGS (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii
Sarah M. McLeod et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
Darren Wong et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Thomas F. Durand-Reville et al.
NATURE MICROBIOLOGY (2017)
Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β-lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β-lactamases
Jason Lickliter et al.
Open Forum Infectious Diseases (2017)
β-Lactamase inhibitors: what you really need to know
Paul G. Ambrose et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
Timothy A. Blizzard et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models
Yuta Yokoyama et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients
Syamhanin Adnan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
分享论文
